Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia

Fabio Guolo,Paola Minetto,Marino Clavio,Maurizio Miglino,Federica Galaverna,Anna Maria Raiola,Carmen Di Grazia,Nicoletta Colombo,Sarah Pozzi,Adalberto Ibatici,Samuele Bagnasco,Daniela Guardo,Annalisa Kunkl,Filippo Ballerini,Chiara Ghiggi,Roberto M. Lemoli,Marco Gobbi,Andrea Bacigalupo

HAEMATOLOGICA（2017）

引用 26|浏览122

暂无评分

摘要

There is increasing evidence that evaluating minimal residual disease (MRD) at various time points during acute myeloid leukemia (AML) therapy retains a strong prognostic value.[1][1]–[3][2] In particular, the persistence of MRD positivity before hematopoietic stem cell transplantation (HSCT) has

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要